Nanoscience and Nanotechnology’s Use in Biomedicine: A Review
Keywords:
Nanotechnology, Biomedicine, Drug Delivery, Diagnostics, Regenerative Medicine, Cancer Therapy, Challenges, Precision Medicine, Personalized Medicine, Safety, Ethics, Future DirectionsAbstract
Nanoscience and nanotechnology have sparked a paradigm change in biomedical research and opened up new possibilities for personalised medicine, treatments, diagnostics. This in-depth analysis navigates the complex environment of nanoscale biological applications. Focusing on the revolutionary potential of nanotechnology, we explore a range of areas, from nanoparticle-mediated drug delivery systems that improve therapeutic precision and reduce side effects to nanoscale imaging methods that revolutionise diagnostics by offering high-resolution insights into biological structures. Additionally, the relationship between
regenerative medicine and nanomaterials is investigated, illuminating how nanotechnology-driven methods promote tissue engineering and organ transplantation. The dynamic relationship between nanotechnology and cancer therapy is also uncovered, demonstrating how nanomaterials support novel immunotherapies and targeted drug delivery for improved cancer treatment. We highlight these innovations, discuss relevant issues like biocompatibility and regulatory issues, indicate potential future
directions like gene editing and AI-assisted nanomedicine. This review highlights the significant influence of nanoscience and nanotechnology on biomedical research horizons and highlights how crucial they are in guiding healthcare towards an era of accuracy, efficacy, patient-centricity.
References
References
Smith JA, Johnson BD. Nanotechnology in Medicine: A Comprehensive Review. Journal of Nanomedicine 2020; 15(3): 231-248.
Williams RG, Thompson LH. Nanoparticle-Based Drug Delivery Systems for Cancer Therapy: Recent Advances
and Future Prospects. Cancer Research 2018; 78(7): 1548-1562.
Brown CM, Davis TP. Nanomaterials for Regenerative Medicine: Current Trends and Future Directions. Biomaterials 2019; 198: 1-11.
Zhang H, Wang Y. Nanotechnology-Enabled Cancer Immunotherapy. Nano Today 2017; 15: 8-12.
Johnson KL, Smith MR. Nanoparticle-Mediated Gene Editing for Targeted Cancer Therapies. Gene Therapy, 2021; 25(4): 175-182.
Lee S, Chen X. Dual-Modality Probes for Imaging and Drug Delivery. Advanced Drug Delivery Reviews 2016; 113: 140-155.
Martinez, J. O., & Silva, G. A. (2017). Challenges and Strategies in Developing Nanomedicines for Brain Diseases. Journal of Controlled Release, 264, 306-312.
Wilson, D. A., & Nolte, R. J. (2018). Nanomachines: Mechanically Interlocked Molecules and Their Applications. Angewandte Chemie International Edition, 57(19), 5048-5058.
Jain, A. K., & Das, M. (2019). Applications of Nanobiotechnology in Cancer Therapeutics. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 11(5), e1561.
Zhang, L., & Gu, F. X. (2019). Principles of Nanoparticle Design for Overcoming Biological Barriers to Drug Delivery. Nature Biotechnology, 37(1), 27-38.
Li, L., & Lu, Y. (2020). A Nanotechnology Approach to Regenerating Tissue and Organ Function. Physiology, 35(1), 10-18.
Davis, M. E., & Chen, Z. G. (2018). Nanoparticle Therapeutics: An Emerging Treatment Modality for Cancer. Nature Reviews Drug Discovery, 7(9), 771-782.
Sun, X., & Liu, C. (2021). Nanomaterials for Photothermal Therapy: A Review. Journal of Photochemistry and Photobiology C: Photochemistry Reviews, 47, 100442.
Maeda, H., & Khatami, M. (2020). Analyses of Long- Term Clinical Data Show That Myeloid Cell-Dense Areas at Tumor Fronts Are Prognostic for Survival. Cancer Immunology, Immunotherapy, 69(12), 2271-2281.
Allen, T. M., & Cullis, P. R. (2013). Liposomal Drug Delivery Systems: From Concept to Clinical Applications. Advanced Drug Delivery Reviews, 65(1), 36-48.
Jokerst, J. V., & Gambhir, S. S. (2013). Molecular Imaging with Theranostic Nanoparticles. Accounts of Chemical Research, 46(8), 1775-1785.
Farokhzad, O. C., & Langer, R. (2009). Impact of Nanotechnology on Drug Delivery. ACS Nano, 3(1), 16-20.
Prow, T. W., & Grice, J. E. (2011). Nanomedicine for Skin Cancer. Advances in Drug Delivery Reviews, 63(8), 650-668.
Peer, D., & Karp, J. M. (2010). Nanocarriers as an Emerging Platform for Cancer Therapy. Nature Nanotechnology, 5(12), 993-1000.
Bobo, D., & DeZazzo, J. (2016). Overcoming Tumor Hypoxia as a Barrier to Radiotherapy, Chemotherapy and Immunotherapy in Cancer Treatment. International Journal of Nanomedicine, 11, 3313-3330.
Published
Issue
Section
Copyright (c) 2023 Journal of Advanced Research in Nanoscience and Nanotechnology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
We, the undersigned, give an undertaking to the following effect with regard to our article entitled
“_______________________________________________________________________________________________________________________________________________________________________________
________________________________________________________________________________” submitted for publication in (Journal title)________________________________________________ _______________________________________________________Vol.________, Year _________:-
1. The article mentioned above has not been published or submitted to or accepted for publication in any form, in any other journal.
2. We also vouchsafe that the authorship of this article will not be contested by anyone whose name(s) is/are not listed by us here.
3. I/We declare that I/We contributed significantly towards the research study i.e., (a) conception, design and/or analysis and interpretation of data and to (b) drafting the article or revising it critically for important intellectual content and on (c) final approval of the version to be published.
4. I/We hereby acknowledge ADRs conflict of interest policy requirement to scrupulously avoid direct and indirect conflicts of interest and, accordingly, hereby agree to promptly inform the editor or editor's designee of any business, commercial, or other proprietary support, relationships, or interests that I/We may have which relate directly or indirectly to the subject of the work.
5. I/We also agree to the authorship of the article in the following sequence:-
Authors' Names (in sequence) Signature of Authors
1. _____________________________________ _____________________________________
2. _____________________________________ _____________________________________
3. _____________________________________ _____________________________________
4. _____________________________________ _____________________________________
5. _____________________________________ _____________________________________
6. _____________________________________ _____________________________________
7. _____________________________________ _____________________________________
8. _____________________________________ _____________________________________
Important
(I). All the authors are required to sign independently in this form in the sequence given above. In case an author has left the institution/ country and whose whereabouts are not known, the senior author may sign on his/ her behalf taking the responsibility.
(ii). No addition/ deletion/ or any change in the sequence of the authorship will be permissible at a later stage, without valid reasons and permission of the Editor.
(iii). If the authorship is contested at any stage, the article will be either returned or will not be
processed for publication till the issue is solved.
